[
  {
    "ts": null,
    "headline": "[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global CRISPR Gene Editing Market size & share revenue was valued at approximately USD 3.65 Billion in 2024 and is expected to reach USD 4.10 Billion in 2025 and is expected to reach around USD 12.6 Billion by 2034, at a CAGR of 13.01% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are CRISPR Therapeutics AG, Agi",
    "url": "https://finnhub.io/api/news?id=5710d3625a2efba60b244e5628d7c1826bf451f4a0d181755881bbfde9c27f89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753385400,
      "headline": "[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136085050,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global CRISPR Gene Editing Market size & share revenue was valued at approximately USD 3.65 Billion in 2024 and is expected to reach USD 4.10 Billion in 2025 and is expected to reach around USD 12.6 Billion by 2034, at a CAGR of 13.01% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are CRISPR Therapeutics AG, Agi",
      "url": "https://finnhub.io/api/news?id=5710d3625a2efba60b244e5628d7c1826bf451f4a0d181755881bbfde9c27f89"
    }
  },
  {
    "ts": null,
    "headline": "Contract research firms' strong earnings signal stabilizing biotech, pharma spending",
    "summary": "(Reuters) -Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending after a cautious stretch driven by tighter sector financing.  Danaher, Medpace, IQVIA, ICON and Thermo Fisher have posted strong results owing to steady demand from the industry for tools and services that are used in the development of novel medicines.  \"Biotech funding has started to tick up month over month from April to June, and perhaps our biggest takeaway from IQVIA results as well as Medpace is that the macro environment, while still challenged, has perhaps stabilized,\" said TD Cowen analyst Charles Rhyee.",
    "url": "https://finnhub.io/api/news?id=388cae48c142f57143332a98c9038540278e95eb8111e4331a4da39ee2adbff5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753378735,
      "headline": "Contract research firms' strong earnings signal stabilizing biotech, pharma spending",
      "id": 136085051,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "(Reuters) -Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending after a cautious stretch driven by tighter sector financing.  Danaher, Medpace, IQVIA, ICON and Thermo Fisher have posted strong results owing to steady demand from the industry for tools and services that are used in the development of novel medicines.  \"Biotech funding has started to tick up month over month from April to June, and perhaps our biggest takeaway from IQVIA results as well as Medpace is that the macro environment, while still challenged, has perhaps stabilized,\" said TD Cowen analyst Charles Rhyee.",
      "url": "https://finnhub.io/api/news?id=388cae48c142f57143332a98c9038540278e95eb8111e4331a4da39ee2adbff5"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
    "summary": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
    "url": "https://finnhub.io/api/news?id=5e0cd1193d047ed1260a68ccf79c213ab0b9cffc2183d4a6d4e09956d253c27b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753374900,
      "headline": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
      "id": 136122463,
      "image": "",
      "related": "TMO",
      "source": "MarketWatch",
      "summary": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
      "url": "https://finnhub.io/api/news?id=5e0cd1193d047ed1260a68ccf79c213ab0b9cffc2183d4a6d4e09956d253c27b"
    }
  },
  {
    "ts": null,
    "headline": "Fibroblast Growth Factors (FGFs) Global Market Report 2025-2029 & 2034 | Regenerative Medicine Demand and Biotech Advancements Fueling Expansion",
    "summary": "The fibroblast growth factors (FGFs) market is projected to soar from $0.86 billion in 2024 to $1.34 billion by 2025, driven by advancements in regenerative medicine, wound healing, and cancer research. Key players like Merck & Co., Thermo Fisher, and Novartis are driving innovation. North America leads, with Asia-Pacific as a fast-growing contender.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The \"Fibroblast Growth Factors (FGFs) Global Market Report 2025\" has been added to ResearchAndMarkets.com'",
    "url": "https://finnhub.io/api/news?id=b8cbdb94d8109d3bae5a1f6df6c92d5635fb1c26afbff6aef8a02d4759bea62f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753366440,
      "headline": "Fibroblast Growth Factors (FGFs) Global Market Report 2025-2029 & 2034 | Regenerative Medicine Demand and Biotech Advancements Fueling Expansion",
      "id": 136066358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The fibroblast growth factors (FGFs) market is projected to soar from $0.86 billion in 2024 to $1.34 billion by 2025, driven by advancements in regenerative medicine, wound healing, and cancer research. Key players like Merck & Co., Thermo Fisher, and Novartis are driving innovation. North America leads, with Asia-Pacific as a fast-growing contender.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The \"Fibroblast Growth Factors (FGFs) Global Market Report 2025\" has been added to ResearchAndMarkets.com'",
      "url": "https://finnhub.io/api/news?id=b8cbdb94d8109d3bae5a1f6df6c92d5635fb1c26afbff6aef8a02d4759bea62f"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Increases Accessibility to Research With the Launches of Scios 3 and Talos 12 Electron Microscopes at M&M 2025 Conference",
    "summary": "WALTHAM, Mass., July 24, 2025--As the world leader in serving science, Thermo Fisher Scientific is proud to announce the launch of two new electron microscopes that will be unveiled at Microscopy & Microanalysis (M&M) in Salt Lake City, Utah, July 27-31, each significantly contributing to the democratization of research in the sciences.",
    "url": "https://finnhub.io/api/news?id=2401acfd846f055784888da2d2ace60129de7dc9438090fdc0f628b01744d000",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753360200,
      "headline": "Thermo Fisher Scientific Increases Accessibility to Research With the Launches of Scios 3 and Talos 12 Electron Microscopes at M&M 2025 Conference",
      "id": 136066438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., July 24, 2025--As the world leader in serving science, Thermo Fisher Scientific is proud to announce the launch of two new electron microscopes that will be unveiled at Microscopy & Microanalysis (M&M) in Salt Lake City, Utah, July 27-31, each significantly contributing to the democratization of research in the sciences.",
      "url": "https://finnhub.io/api/news?id=2401acfd846f055784888da2d2ace60129de7dc9438090fdc0f628b01744d000"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Jul 24, 2025",
    "summary": "Companies In The News Are: T, TMO, GD, BSX.",
    "url": "https://finnhub.io/api/news?id=95e85fe9d8e79125a0abc05b0556b3699f43ef67353c2ff55da2c05f7500b473",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753348620,
      "headline": "Company News for Jul 24, 2025",
      "id": 136066365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Companies In The News Are: T, TMO, GD, BSX.",
      "url": "https://finnhub.io/api/news?id=95e85fe9d8e79125a0abc05b0556b3699f43ef67353c2ff55da2c05f7500b473"
    }
  },
  {
    "ts": null,
    "headline": "TMO Q2 Deep Dive: Pharma Strength, Tariff Adaptation, and Strategic Investments Shape Outlook",
    "summary": "Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 3% year on year to $10.86 billion. Its non-GAAP profit of $5.36 per share was 2.5% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=3fc3b8469fd79fa08acceed0e25c674046f55e5f91425ac9b8ee10d0843b1121",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753335350,
      "headline": "TMO Q2 Deep Dive: Pharma Strength, Tariff Adaptation, and Strategic Investments Shape Outlook",
      "id": 136066440,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 3% year on year to $10.86 billion. Its non-GAAP profit of $5.36 per share was 2.5% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=3fc3b8469fd79fa08acceed0e25c674046f55e5f91425ac9b8ee10d0843b1121"
    }
  }
]